EUCTR2004-001551-11-SE进行中（未招募）不适用
Behandling av förhöjt pulmonellt arteriellt tryck med inhalerad iloprost - Iloprost
und University Hospital0 个研究点目标入组 40 人开始时间: 2004年8月13日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inklusionskriterier:
- •- Respiratorvård pga RDS, mekoniumaspiration eller primär lunghypertension.
- •- Gestationsålder 24 veckor eller mera
- •- Postnatal ålder 0-24 t (- 48 t) timmar
- •- Föräldrarnas tillstånd
- •- Inga betydande anomalier
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exklusionskriterier:
- •- Betydande anomalier
- •- Ålder över 48 timmar
- •- Patienten är redan inkluderad i en pågående studie vid namn ”IGF-studie”
研究者
相似试验
进行中（未招募）
1 期
Racecadotril used in combination with sildenafil to reduce blood pressure in the lungs.Pulmonary hypertensionMedDRA version: 14.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-003921-13-GBniversity College London21
进行中（未招募）
不适用
Prevention of Established Pulmonary Hypertension in High Risk patients with Fibrotic Lung Disease – a double-blinded, randomised, placebo controlled trial with endothelin-1 receptor antagonist therapy - Prevention of Pulmonary Hypertension in Interstitial Lung DiseaseEUCTR2007-001645-17-GBRoyal Brompton and Harefield NHS Trust
进行中（未招募）
1 期
Frühtherapie der pulmonal arteriellen Hypertonie (PAH)Exercise induced pulmonary hypertension in patients with connective tissue disaesesEUCTR2007-004288-23-ATMedizinische Universität Graz
已完成
不适用
Pulmonary artERial hypertenSion: bonE morPHOgeNEtic protein signaling out of control (PERSEPHONE)1004697310037454Pulmonary arterial hypertensionNL-OMON55717VU medisch centrum100
进行中（未招募）
1 期
Treatment of portopulmonary hypertension (high blood pressure in the pulmonary circulation) with ambrisentan (a medicinal product for the therapy of portopulmonary hypertension).Portopulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome HPS are present in a considerable number of patients with compensated cirrhosis. Treatment of PoPH with ambrisentan is well tolerated and improves hemodynamics as well as symptoms and physical capacity.MedDRA version: 14.0 Level: PT Classification code 10067281 Term: Portopulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-001139-22-ATMedizinische Universität Graz, Klin. Abteilung für Gastroenterologie und Hepatologie12